The neutrophil-to-lymphocyte ratio (NLR) is an independent factor for overall survival (OS) in patients with metastatic melanoma, whether they receive targeted therapy or immunotherapy. In a retrospective analysis performed in patients treated at a single institution, Overall survival was markedly improved in patients with an NLR <5 at a median of 14.8 months compared with those who had an NLR >5, in whom the median OS was 5 months, according to research presented by Elizabeth Blackley, MD, at the 2017 ESMO Congress.
My NLR was 3.4 when my treatment started and is now 2.2.
As there is nothing written about results of immunotherapy for Mucosal Melanoma with metastasis in the bones (stage IV-C) patients like me, this is one of the first really tangible positive indicators. Yes!
Reference article.
No comments:
Post a Comment